Transcriptome Analysis in Tumor Microenvironment and Tumor Heterogeneity

Submission Deadline: 30 August 2023 Submit to Special Issue

Guest Editors

Jinhui Liu, The First Affiliated Hospital of Nanjing Medical University, China. E-mail: Jinhuiliu@njmu.edu.cn

Peixin Dong, Hokkaido University, Japan. E-mail:dpx1cn@med.hokudai.ac.jp

Jiaheng Xie, The First Affiliated Hospital of Nanjing Medical University, China. E-mail: xiejiaheng@njmu.edu.cn

Summary

The tumor microenvironment encompasses not only the tumor cells themselves, but also the surrounding fibroblasts, immunological and inflammatory cells, glial cells, and other cells, as well as interstitial cells, microvessels, and biomolecules infiltrating the surrounding area. Tumor occurrence, development, and metastasis are all influenced by the tumor cells' internal and external environments. Changes in metabolism, secretion, immunology, shape, and function in systemic and local tissues can also restrict and impact the onset and development of tumors.

 

Malignant cells diversify and become more heterogeneous during carcinogenesis and metastasis. As a result, several immune-related components, such as the cytokine/chemokine environment, cytotoxic activities, or immunosuppressive factors, may infiltrate tumors. Almost all solid tumors include heterogeneity, which varies geographically and temporally with tumor progression and treatment intervention. Anti-tumor immune heterogeneity is linked to disease progression and treatment reactivity, particularly in immunotherapy.

 

The advent of next-generation sequencing technology (NGS) is allowing cancer centers all around the world to deliver tailored treatment, particularly for malignancies that have no defined treatment plan now. Personalized therapy is a novel treatment based on the tumor's genetic characteristics. It has nothing to do with the tumor's origin tissue, but it does necessitate understanding how changes in tumor microgenetics, tumor microenvironment, cell heterogeneity, and cell interaction ultimately lead to tumor growth, vulnerability, and treatment response. The molecular profile and functional responses of tumor cells, as well as the composition, spatial organization, and interactions of the cells that make up tumor tissue, can now be analyzed in great detail thanks to technological advancements.

 

Currently, multi-omics analysis has greatly improved our understanding of tumor microenvironment and tumor heterogeneity. Recent research has proven the promise of examining the complexity of tumor immunological heterogeneity and its therapeutic relevance in immunotherapy using multi-omics sequencing, single-cell sequencing, and longitudinal liquid biopsy approaches. Exploring the mechanisms of tumor microenvironment heterogeneity will help us better understand tumor heterogeneity in the clinic, allowing us to build more effective customized therapies.

 

This topic aims to focus on the advances in the discovery of tumor microenvironment and tumor heterogeneity based on muti-omics analysis. We welcome the submission of original research and review articles that include biomarkers in clinical studies and applications, as well as technologies or discoveries in experimental approaches.

 

• Novel biomarkers in the tumor microenvironment.

• Stratification of tumor patients based on the changes in the tumor microenvironment.

• Study on the regulatory mechanism of tumor immune microenvironment.

• Using second-generation sequencing (NGS) to explore the gene profile in the tumor microenvironment.

• Exploration of the tumor microenvironment and tumor heterogeneity based on single-cell sequencing analysis.

• Bioinformatics analysis to construct prognostic models associated with tumor microenvironment and tumor heterogeneity.


Keywords

Tumor microenvironment; Tumor heterogeneity; Multi-omics analysis; Tumor immunity; Immunotherapy

Published Papers


  • Open Access

    ARTICLE

    High expression of PD-L1 mainly occurs in non-small cell lung cancer patients with squamous cell carcinoma or poor differentiation

    LU LIU, BIN XIE, WEI ZHU, QIUYAN HE, JIANHUA ZHOU, SHUANG LIU, YONGGUANG TAO, DESHENG XIAO
    Oncology Research, Vol.31, No.3, pp. 275-286, 2023, DOI:10.32604/or.2023.028227
    (This article belongs to this Special Issue: Transcriptome Analysis in Tumor Microenvironment and Tumor Heterogeneity)
    Abstract Background: Lung cancer is one of the most lethal cancers worldwide, but studies have shown that the higher the expression of programmed cell death protein 1 ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC), the more likely it will benefit from anti-PD-L1 immunotherapy. The purpose of our study was to collect and analyze abundant clinical samples in order to provide evidence for clinicians and patients who might consider anti-PD-L1 immunotherapy while jointly formulating treatment plans. Methods: On the one hand, we obtained cases from The Cancer Genome Atlas (TCGA) database, including 498 lung squamous cell cancer (LUSC) patients and… More >

  • Open Access

    ARTICLE

    Apolipoprotein C1 promotes tumor progression in gastric cancer

    QIOU GU, TIAN ZHAN, XIAO GUAN, CHUILIN LAI, NA LU, GUOGUANG WANG, LEI XU, XIANG GAO, JIANPING ZHANG
    Oncology Research, Vol.31, No.3, pp. 287-297, 2023, DOI:10.32604/or.2023.028124
    (This article belongs to this Special Issue: Transcriptome Analysis in Tumor Microenvironment and Tumor Heterogeneity)
    Abstract Background: Gastric cancer (GC) is a malignancy with the worst prognosis that seriously threatens human health, especially in East Asia. Apolipoprotein C1 (apoc1) belongs to the apolipoprotein family. In addition, apoc1 has been associated with various tumors. However, its role in GC remains unclear. Methods: Firstly, we quantified its expression in GC and adjacent tumor tissues, using The Cancer Genome Atlas (TCGA). Next, we assessed cell invasion and migration abilities. Finally, we revealed the role of apoc1 in the tumor microenvironment (TME), immune cell infiltration and drug sensitivity. Results: Firstly, in TCGA database, it has been shown that elevated expression… More >

  • Open Access

    ARTICLE

    Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma

    WEI BAO, QIANGUANG HAN, XIAO GUAN, ZIJIE WANG, MIN GU
    Oncology Research, Vol.31, No.2, pp. 181-192, 2023, DOI:10.32604/or.2023.028051
    (This article belongs to this Special Issue: Transcriptome Analysis in Tumor Microenvironment and Tumor Heterogeneity)
    Abstract Background: Clear-cell renal cell carcinoma (ccRCC) is the most common malignant kidney cancer. However, the tumor microenvironment and crosstalk involved in metabolic reprogramming in ccRCC are not well-understood. Methods: We used The Cancer Genome Atlas to obtain ccRCC transcriptome data and clinical information. The E-MTAB-1980 cohort was used for external validation. The GENECARDS database contains the first 100 solute carrier (SLC)-related genes. The predictive value of SLC-related genes for ccRCC prognosis and treatment was assessed using univariate Cox regression analysis. An SLC-related predictive signature was developed through Lasso regression analysis and used to determine the risk profiles of patients with… More >

Share Link